Multicenter phase III clinical trial of otilonium bromide in irritable bowel syndrome [2]

Indian Journal of Gastroenterology

Volumn 21, Issue 2, 2002, Pages 85-86

  Kaushik, A ^a   Pursnani, M L ^a   Kar, P ^a  

^a Allahabad Bank Building   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; OTILONIUM BROMIDE; SPASMOLYTIC AGENT;

ADULT; ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; IRRITABLE COLON; LETTER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY;

ADULT; CALCIUM CHANNEL BLOCKERS; COLONIC DISEASES, FUNCTIONAL; HUMANS; QUATERNARY AMMONIUM COMPOUNDS;

EID: 0036227314     PISSN: 02548860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
2. Blocking effects of otilonium bromide on calcium channels and secretion in rat chromaffin cells
3. Otilonium bromide: A smooth muscle relaxant that interferes with calcium mobilization
4. A study of the absorption of otilonium bromide following oral administration in man
5. The irritable bowel syndrome: A cross-over study of otilonium bromide, mebeverine and placebo
6. Otilonium bromide in IBS: A double blind placebo-controlled 15-week-tudy